[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-363580-105":59,"doc-detail-363580-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","patient-derived-organoids-in-gastric-cancer-bridging-the-tumor-microenvironment-to-functional-precision-oncology","Patient-derived organoids in gastric cancer - bridging the tumor microenvironment to functional precision oncology","","Gastric cancer combines profound molecular heterogeneity with a dynamically evolving tumor microenvironment (TME), limiting the predictive power of genomic sequencing for individual therapy response. Patient-derived cancer organoids (PDCOs) offer high-fidelity 3D models that recapitulate tumor histology, mutational landscapes, and functional phenotypes. This review summarizes how PDCOs model TME features and immune evasion, discusses their value as “patient avatars” for functional precision oncology, and evaluates approaches such as artificial intelligence and 3D bioprinting. It also outlines a roadmap for clinical integration to support individualized regimens.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/patient-derived-organoids-in-gastric-cancer-bridging-the-tumor-microenvironment-to-functional-precision-oncology/363580/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/patient-derived-organoids-in-gastric-cancer-bridging-the-tumor-microenvironment-to-functional-precision-oncology/363580.png","ImageObject",300,407,{"name":92,"@type":93},"Elsa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is genomic sequencing insufficient for predicting gastric cancer treatment outcomes?","Question",{"text":112,"@type":113},"Genomic sequencing can identify actionable mutations but often cannot capture complex, dynamically evolving in vivo tumor microenvironment interactions that drive functional therapeutic responses.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do patient-derived cancer organoids (PDCOs) offer over conventional 2D cell lines?",{"text":117,"@type":113},"PDCOs can be established from surgical resections or biopsies and maintain key tumor features, including histological structure and mutational landscapes, while 2D lines may lose tumor characteristics during prolonged passaging.",{"name":119,"@type":110,"acceptedAnswer":120},"How do PDCOs contribute to functional precision oncology for gastric cancer?",{"text":121,"@type":113},"PDCOs serve as high-fidelity “patient avatars” that enable scalable ex-vivo assessment of chemotherapy, targeted therapies, and immunotherapies within a clinically actionable timeframe, with early studies showing high clinical concordance.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},363580,1790469745,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","OPEN ACCESS  \nEDITED BY  \nZe Xiang,  \nZhejiang University, China  \nREVIEWED BY  \nRenuka Dahiya,  \nUniversity at Buffalo, United States Yutong Li,  \nDana–Farber Cancer Institute, United States  \n*CORRESPONDENCE  \nJi Ma,  \n [mj32202022@163.com](mj32202022@163.com)[ ](mj32202022@163.com)Chuan Jiang,  \n [jiangch123@126.com](jiangch123@126.com)  \n†These authors share first authorship  \nRECEIVED 19 January 2026  \nREVISED 28 April 2026  \nACCEPTED 07 May 2026  \nPUBLISHED 22 May 2026  \nCITATION  \nMa J, Liu X, Xu H and Jiang C (2026) Patient-derived organoids in gastric cancer: bridging the tumor microenvironment to functional precision oncology.  \nFront. Bioeng. Biotechnol. 14:1790902 .  \ndoi: 10.3389/fbioe.2026.1790902  \nCOPYRIGHT  \n© 2026 Ma, Liu, Xu and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nTYPE Review  \nPUBLISHED 22 May 2026  \nDOI 10.3389/fbioe.2026.1790902  \nPatient-derived organoids in gastric cancer: bridging the tumor microenvironment to functional precision oncology  \nJi Ma 1*†, Xinyang Liu 2†, Hongtao Xu 1 and Chuan Jiang 1* 1Gastrointestinal Surgery Department, Lishui Municipal Central Hospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China, 2Department of Dermatology, Lishui Municipal Central  \nHospital, The Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, China  \nGastric cancer (GC) represents a formidable global health challenge characterized by profound molecular heterogeneity and a dynamically evolving tumor microenvironment (TME) . Although genomic sequencing facilitates precision medicine, its capacity to capture intricate tumor microenvironment interactions or predict individual therapeutic outcomes remains limited. Recently, patient-derived cancer organoids (PDCOs) have emerged as highfidelity three-dimensional (3D) models that faithfully recapitulate the histological architecture, mutational landscapes, and functional phenotypes of their parent tumors. This review systematically delineates advances in using GCPDCOs to simulate the TME and elucidate immune evasion mechanisms, specifically camouflage, coercion, and cytoprotection. We emphasize the transformative potential of PDCOs as “patient avatars” in functional precision oncology, highlighting their promising predictive value for sensitivities to chemotherapy, targeted therapies, and immunotherapies, with early smallcohort studies demonstrating high clinical concordance. Furthermore, we evaluate the integration of emerging technologies, such as artificial intelligence and 3D bioprinting, to overcome current translational bottlenecks. Finally, we propose a strategic roadmap for integrating organoid technology into clinical workflows to achieve truly individualized therapeutic regimens for every gastric cancer patient.  \nKEYWORDS  \ngastric cancer, immune evasion, patient-derived organoids, precision oncology, tumor microenvironment  \n1 Introduction  \nGastric cancer (GC) remains a formidable global health challenge, ranking as the fifth most frequently diagnosed malignancy and a leading cause of cancer-related mortality worldwide (Kan et al., 2025). According to 2022 statistics, GC accounted for approximately 970,000 new cases and 660,000 deaths annually, highlighting its status as a primary driver of the global cancer burden (Bray et al., 2024) . Despite advancements in screening and multimodality treatments, the clinical prognosis remains suboptimal, primarily due to the subtle nature of early symptoms leading to frequent late-stage diagnoses when curative options are limited (Migliore et al., 2025) . The d","cbCairtztKufvpwn","https://ap.wps.com/l/cbCairtztKufvpwn","pdf",4155401,22,"English","# Introduction\n## Global burden and clinical limitations of gastric cancer\n## Rationale for functional precision medicine\n# Patient-derived cancer organoids and modeling the TME\n## Advantages over 2D cell lines\n## Ex-vivo drug testing for therapy sensitivity\n# Immune evasion mechanisms in the organoid context\n## Camouflage, coercion, and cytoprotection\n# Emerging integrations and translational roadmap\n## Artificial intelligence and 3D bioprinting\n## Clinical workflow strategies","[{\"question\":\"Why is genomic sequencing insufficient for predicting gastric cancer treatment outcomes?\",\"answer\":\"Genomic sequencing can identify actionable mutations but often cannot capture complex, dynamically evolving in vivo tumor microenvironment interactions that drive functional therapeutic responses.\"},{\"question\":\"What advantages do patient-derived cancer organoids (PDCOs) offer over conventional 2D cell lines?\",\"answer\":\"PDCOs can be established from surgical resections or biopsies and maintain key tumor features, including histological structure and mutational landscapes, while 2D lines may lose tumor characteristics during prolonged passaging.\"},{\"question\":\"How do PDCOs contribute to functional precision oncology for gastric cancer?\",\"answer\":\"PDCOs serve as high-fidelity “patient avatars” that enable scalable ex-vivo assessment of chemotherapy, targeted therapies, and immunotherapies within a clinically actionable timeframe, with early studies showing high clinical concordance.\"}]","Patient-derived organoids in gastric cancer - bridging the tumor microenvironment to functional precision oncology | PDF",1790151931,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b06741b4e1b9410013359c6e278424d1.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11452e9a16467e27fb858a2bb8bfae65.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b16b90098acf33656f7267bc89c0c24.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/87fb8838cb2751f3828164bc38a4b0bf.webp",980,1385]